Obsidian Therapeutics (NASDAQ:OBX) Stock Has Consensus Price Target of $39.00

Shares of Obsidian Therapeutics (NASDAQ:OBX) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $39.00.

Several analysts have recently weighed in on the stock. Weiss Ratings began coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They issued a “sell (d-)” rating for the company. TD Cowen started coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating on the stock. Piper Sandler assumed coverage on Obsidian Therapeutics in a report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective on the stock. Wall Street Zen upgraded Obsidian Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, September 27th. Finally, Lifesci Capital assumed coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $43.00 target price for the company.

Obsidian Therapeutics Stock Down 4.5%

Obsidian Therapeutics stock opened at $13.22 on Friday. The stock’s 50-day moving average price is $18.61. Obsidian Therapeutics has a 12-month low of $12.16 and a 12-month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.